Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Multiple myeloma molecular subtype and application

A technology for multiple myeloma and tumor patients, applied in special data processing applications, biochemical equipment and methods, instruments, etc., can solve the problem of multiple myeloma etiological associations that have not been elucidated, cannot predict drug treatment response, and cannot be used for plasma cells. developmental process-related issues

Active Publication Date: 2018-09-25
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the above molecular typing and expression signatures are not predictive of drug response, nor can they be correlated with plasma cell development, and the association between the genes used for molecular typing and the etiology of multiple myeloma has not been elucidated

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Multiple myeloma molecular subtype and application
  • Multiple myeloma molecular subtype and application
  • Multiple myeloma molecular subtype and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0067] Example 1. Screening of molecular diagnostic markers for multiple myeloma and implementation of molecular typing

[0068] Using the multiple myeloma expression data set GSE2658 provided by the NCBI GEO public database, through Pearson correlation analysis, 87 genes co-expressed with MCL1 were obtained. -M gene enriched in multiple myeloma samples. For more stable molecular typing, 36 of the 133 genes with low classification efficiency were further screened, and finally 97 classified genes with stable differential expression and relatively high abundance were retained.

[0069] The names of the 97 genes are as follows:

[0070] ACBD3, ADAR, ADSS, ALDH2, ANP32E, ANXA2, ATF3, ATP8B2, CACYBP, CAPN2, CCND1, CCT3, CDC42SE1, CERS2, CHSY3, CLIC1, CLMN, COPA, CSNK1G3, DAP3, DENND1B, ENSA, EPRS, EPSTI1, EVL, FAM13A, FAM49A, FLAD1, FRZB, GLRX2, HAX1, HDGF, HLA-A, HLA-B, HLA-C, HLA-F, HLA-G, IL6R, ISG20L2, JTB, KLF2, LAMTOR2, LDHA, MCL1, MOXD1, MRPL24, MRPL9, MVP, MYL6, NDUFS2, ...

Embodiment 2

[0088] Example 2. Application of Bayesian classifier of multiple myeloma in predicting patient prognosis and survival rate

[0089] 1. Database GSE2658

[0090] According to the expression data of 97 classified genes in 551 multiple myeloma patient samples (detected before treatment) in the GSE2658 database, the 551 samples were classified by the Bayesian classifier of multiple myeloma obtained in Example 1, and 249 Cases of MCL1-M-High subtype multiple myeloma and 302 MCL1-M-Low subtype multiple myeloma.

[0091] 551 sample patients were followed up for 72 months after treatment. According to the follow-up results, survival analysis (K-M analysis and cox regression analysis) was performed. The results are as follows Figure 4 As shown, it can be seen that the two multiple myeloma subtypes, MCL1-M-High and MCL1-M-Low, have significantly different prognosis, and the overall survival rate of the MCL1-M-High subtype is higher than that of the MCL1-M-Low subtype. type was lower ...

Embodiment 3

[0100] Example 3. Molecular diagnostic markers and typing of multiple myeloma in predicting whether the patient to be tested can be treated with bortezomib

[0101] The GSE19784 multiple myeloma expression dataset was obtained from a clinical trial of a phase III drug (HOVON-65 / GMMG-HD4), with the patient's drug regimen. The trial randomly divided patients into two groups to receive VAD (155 cases) and PAD (148 cases) two drug combinations, the difference between the two is that the PAD regimen has more bortezomib (trade name: Velcade). The gene expression data of the enrolled patients were collected before treatment.

[0102] The patients were stratified according to the above-mentioned MCL1-M molecular classification, and then were divided into two subgroups, MCL1-M-High (51 PAD, VAD 56) and MCL1-M-Low (PAD 104, VAD 92). The patients were divided into groups according to the drug treatment plan and the survival analysis (K-M analysis and cox regression analysis) was carried...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a multiple myeloma molecular subtype and application. The product provided by the invention comprises a substance for obtaining or detecting 97 gene expressions in a multiple myeloma cancer patient to be detected. The product further comprises equipment for operating a multiple myeloma Bayes classifier. In the invention, a gene module (MCL1-M for short) co-expressed with anMCL1 gene is identified, and the gene module is applied to divide multiple myeloma into two main subtypes, namely an MCL-M-High subtype and an MCL-M-Low subtype. The two subtypes have prognosis and genetics characteristics which are significantly different.

Description

technical field [0001] The invention belongs to the field of biotechnology, and in particular relates to molecular typing and application of multiple myeloma. Background technique [0002] Multiple Myeloma (MM) is a tumor caused by the malignant proliferation of plasma cells, and is the second most common blood tumor, with an incidence of 1-2 / 100,000 people in China. Multiple myeloma is a common disease in the elderly over 60 years old. With the aggravation of aging in my country, the incidence rate is increasing year by year, and it has become a disease that seriously threatens the health of the elderly. Multiple myeloma is typically characterized by the presence of large numbers of abnormally proliferating plasma cells in the bone marrow that secrete an abnormal immunoglobulin or immunoglobulin fragment, the M protein. [0003] Survival in multiple myeloma has improved markedly with the introduction of proteasome inhibitors such as bortezomib and immunomodulatory drugs su...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886G06F19/24
CPCC12Q1/6886C12Q2600/118C12Q2600/158G16B40/00
Inventor 樊小龙阿亚兹·阿里·萨莫李玖一卢绪章
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com